Neurocrine Biosciences (NBIX) was Initiated by Needham to “Buy” and the brokerage firm has set the Price Target at $62. Needham advised their investors in a research report released on Oct 18, 2016.
Many Wall Street Analysts have commented on Neurocrine Biosciences. Leerink Partners Resumed Neurocrine Biosciences on Oct 4, 2016 to “Outperform”, Price Target of the shares are set at $70.
On the company’s financial health, Neurocrine Biosciences reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.49.During the same quarter in the previous year, the company posted $-0.28 EPS.
Neurocrine Biosciences closed down -1.89 points or -4.28% at $42.27 with 7,42,990 shares getting traded on Friday. Post opening the session at $44.39, the shares hit an intraday low of $42.22 and an intraday high of $44.62 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Sep 2, 2016, Malcolm Lloyd-smith (Chief Regulatory Officer) sold 9,000 shares at $50.00 per share price. According to the SEC, on Aug 16, 2016, Christopher Flint Obrien (Chief Medical Officer) sold 12,500 shares at $48.73 per share price. On Aug 9, 2016, Corinne H Nevinny (director) sold 5,000 shares at $48.54 per share price, according to the Form-4 filing with the securities and exchange commission.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.